FivePrime and Pfizer (PFE) Enter Oncology and Diabetes Collaboration
More News related to PFE
- Safe-BioPharma Recommends DEA Use Existing Federal Infrastructure to Manage ePrescriptions for Controlled Substances
- New Data across Pfizer's Pain and Inflammation Portfolio to Be Presented at Upcoming ACR Meeting
- EPA Honors Pfizer for Reducing Greenhouse Gas Emissions
- David Moenning's Daily State of the Markets: 10/08
- Merrill Lynch Upgrades Pfizer (PFE) to Buy
More News related to Corporate News
- AIG Issues Statement in Response to NY AG Cuomo's Letter to the AIG Board of Directors
- Valspar (VAL) Renews Share Repurchase Authorization of 4M Shares
- BioMarin Pharma (BMRN) Announces Results from Phase 2a Study of 6R-BH4
- Autodesk (ADSK) Completes Acquisition of Electrical Computer-Aided Design ECSCAD Technology
- Air Products (APD) Announces Recent Investments in Europe
Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE: PFE) announced the initiation of a worldwide collaborative research and license agreement. The collaboration will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes. Under the collaboration, FivePrime will screen its comprehensive protein library in both cell-based assays and primary in vivo screens directed toward finding potential therapeutic protein products and antibody targets.
Related Categories
Corporate NewsStocks Mentioned
-0.86Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
